Lamprene 100mg capsule

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

clofazimine, Quantity: 100 mg

Available from:

Novartis Pharmaceuticals Australia Pty Ltd

Pharmaceutical form:

Capsule, soft

Composition:

Excipient Ingredients: sodium ethyl hydroxybenzoate; white beeswax; Rape Seed Oil; acetanisole; sodium propyl hydroxybenzoate; butylated hydroxytoluene; ethyl vanillin; iron oxide red; propylene glycol; iron oxide black; hydrogenated vegetable oil; Gelatin; glycerol; lecithin; citric acid monohydrate

Administration route:

Oral

Units in package:

1000

Class:

Medicine Registered

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

This product accepted for registration as 'currently supplied' at the time of commencement of the Act. Changes in Directions for Use were approved as specified in the letter of 29 June 1992 from Dr Alex Proudfoot. Indicated for treatment for multi-bacillary forms of leprosy.

Product summary:

Visual Identification: Soft reddish brown oblong gelatine capsule marked GM, GEIGY on reverse; Container Type: Bottle; Container Material: HDPE; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Registered

Authorization date:

1991-08-02